344 related articles for article (PubMed ID: 9037359)
1. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
3. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
4. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
5. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
[TBL] [Abstract][Full Text] [Related]
6. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.
Toner GC; Stockler MR; Boyer MJ; Jones M; Thomson DB; Harvey VJ; Olver IN; Dhillon H; McMullen A; Gebski VJ; Levi JA; Simes RJ
Lancet; 2001 Mar; 357(9258):739-45. PubMed ID: 11253966
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.
Horwich A; Dearnaley DP; Nicholls J; Jay G; Mason M; Harland S; Peckham MJ; Hendry WF
J Clin Oncol; 1991 Jan; 9(1):62-9. PubMed ID: 1702147
[TBL] [Abstract][Full Text] [Related]
9. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
Necchi A; Mariani L; Di Nicola M; Lo Vullo S; Nicolai N; Giannatempo P; Raggi D; Farè E; Magni M; Piva L; Matteucci P; Catanzaro M; Biasoni D; Torelli T; Stagni S; Bengala C; Barone C; Schiavetto I; Siena S; Carlo-Stella C; Pizzocaro G; Salvioni R; Gianni AM
Ann Oncol; 2015 Jan; 26(1):167-172. PubMed ID: 25344361
[TBL] [Abstract][Full Text] [Related]
10. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy.
Pectasides D; Pectasides M; Farmakis D; Nikolaou M; Koumpou M; Kostopoulou V; Mylonakis N
Eur Urol; 2004 Feb; 45(2):187-93. PubMed ID: 14734005
[TBL] [Abstract][Full Text] [Related]
11. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G
Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633
[TBL] [Abstract][Full Text] [Related]
12. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
[TBL] [Abstract][Full Text] [Related]
15. An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.
Giesen E; Mager A; van Tinteren H; Rodenhuis S; Kerst JM
Urol Oncol; 2013 Jan; 31(1):110-4. PubMed ID: 21458311
[TBL] [Abstract][Full Text] [Related]
16. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours.
Horwich A; Bliss J
Ann Oncol; 1996 Dec; 7(10):989-91. PubMed ID: 9037354
[No Abstract] [Full Text] [Related]
18. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Johnson D; Elson P; Einhorn LH; Trump D
J Clin Oncol; 1995 Feb; 13(2):470-6. PubMed ID: 7531223
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.
Tjulandin SA; Garin AM; Mescheryakov AA; Perevodchikova NI; Gorbunova VA; Sokolov AV; Ljubimova NV; Mironova GT; Molchanov GV; Ozols RF
Ann Oncol; 1993 Sep; 4(8):663-7. PubMed ID: 8240996
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of carboplatin dose escalation in combination chemotherapy with etoposide, bleomycin and GM-CSF support for poor prognosis nonseminomatous germ cell tumors patients.
Tjulandin SA; Stenina MB; Sidorova NJ; Delgado FG; Sokolov AV; Molchanov GV; Ljubimova NV; Garin AM
Neoplasma; 1996; 43(5):347-52. PubMed ID: 8996556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
